Please assess the completion status of the following clinical trial:

Trial Title: Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: between 50-80 years.~* Primary TKA surgery.~Exclusion Criteria:~1. Previous TKA and/or total hip arthroplasty surgery (older subjects).~2. Dementia or related mental issues that may potentially put the subject at risk as determined by the surgeon.~3. Untreated endocrine disease (Hypo/Hyperthyroidism, Addison's or Cushing's syndrome, etc.).~4. Significant heart, liver, kidney, blood, or respiratory disease.~5. Peripheral vascular disease.~6. Active cancer.~7. Recent (within 6 months) treatment with anabolic steroids.~8. Alcohol or drug abuse.~9. Inability to have MRI

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Essential Amino Acids (EAA) (Type: EXPERIMENTAL): Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%).
- Placebo (Alanine) (Type: PLACEBO_COMPARATOR): Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine.

Based on this trial design, predict the completion outcome and termination type (if applicable).